Stryker Settles for $15 Million in Bone Filler Misbranding Case
Stryker’s Biotech division has agreed to pay $15 million to the U.S. government to settle an illegal scheme to promote off-label use of its OP-1 implant and OP-1 putty in combination with Calstrux, a bone-void filler.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.